Based on their genome-wide loss-of-function CRISPR-Cas9 screens on three ibrutinib-sensitive ABC cell lines, one ibrutinib-insensitive ABC cell line, and four ibrutinib-insensitive GCB cell lines, they uncovered a new B-cell receptor signaling in ibrutinib-responsive cell lines which is coordinated by a multiprotein supercomplex formed by MYD88, TLR9, and the BCR (My-T-BCR supercomplex) (Phelan et al., 2018). This evidence concerns the gene BCR and aneurysmal bone cyst.